CD lymph node

Many patients and doctors have questions about Castleman disease. We are here to help share what is known and to push forward research to answer those questions that are not yet answered.

The immune system attacks vital organs

Castleman disease (CD) describes a group of three heterogeneous inflammatory disorders that occur in people of all ages and share a similar lymph node appearance under the microscope.

A healthy immune system involves a complex and interconnected network of cells and inflammatory messengers (cytokines), which signal for the immune system to activate. Lymph nodes are the home base for immune cells.

In Castleman disease patients, these inflammatory cells become activated and produce an excess of inflammatory messengers (cytokines), particularly Interleukin-6 (IL-6), which can lead to dysfunction of the organ. This dysfunction includes lymph node enlargement, flu-like symptoms (e.g., fatigue, night sweats, nausea, weight loss), and dysfunction of vital organs, including the liver, kidneys, and bone marrow (e.g., fluid gain, confusion, bruising, bleeding).

A wide-ranging disease that is difficult to diagnose


Castleman disease is classified first based on the number of lymph node regions that are affected. CD can occur in a single region of enlarged lymph nodes (unicentric Castleman disease or UCD) or multiple regions of enlarged nodes (multicentric Castleman disease or MCD). Multicentric Castleman disease, or MCD, should be further subdivided based on the presence of Human Herpes Virus-8 (HHV-8) into HHV-8-associated MCD and HHV-8-negative or idiopathic MCD (iMCD). HHV-8-associated MCD cases are often also HIV-positive, but there are also HIV-negative individuals with HHV-8-associated MCD. If the patient is HIV-negative and his/her lymph node and/or blood sample are HHV-8-negative, that case is considered to be HHV-8-negative or idiopathic MCD (iMCD). It is important to distinguish these three entities since they require entirely different therapeutic approaches.

To make things more complex, there is no official diagnostic criteria for Castleman disease and the lymph node features found in Castleman disease can also be seen in other diseases including cancers and autoimmune diseases (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma, Systemic Lupus Erythematous, Rheumatoid Arthritis). The CDCN is currently working to establish international diagnostic criteria for iMCD.


Unicentric Castleman disease


HHV-8-associated Multicentric CD -


Idiopathic Multicentric Castleman disease (iMCD)

% of Cases




Regions Affected

Enlarged lymph node in one region

Multiple regions of enlarged nodes

Multiple regions of enlarged nodes

Common Age of Diagnosis

Mostly in children and young adults, but can occur at any age

Mostly in adults 40-60 years old, but can occur at any age

Mostly in adults 40-60 years old, but can occur at any age


Slightly more common in females

More common in males

Slightly more common in males


Usually shows no symptoms, but there can be discomfort associated with an enlarged lymph node and occasionally “Multicentric Castleman disease -like” symptoms

Wide range from mild flu-like symptoms to severe episodes of sepsis-like, life-threatening organ failure and death

Wide range from mild flu-like symptoms to severe episodes of sepsis-like, life-threatening organ failure and death


Unknown, but can be associated with paraneoplastic pemphigus - a deadly autoimmune disorder that occurs secondary to an underlying malignancy

Human Herpes Virus-8 (HHV-8) is responsible for triggering the disease, and patients are often immunocompromised (e.g., HIV, organ transplantation)

The driver of the disease is unknown


Surgical removal of the enlarged node usually cures the patient

Well controlled with B-cell depletion therapy with rituximab

Treatment typically involves anti-IL-6 therapy, with or without chemotherapy

Chance of Relapse


Less common than iMCD with close monitoring

Common, but varies depending on treatment used


With surgical removal most symptoms go away. There have not been any reported cases of UCD transforming into MCD.

None – We need your help to find it

None – We need your help to find it

5-year Survival Rate

90% - 1 in 10 die

62% - 1 in 3 die, but new data shows patients treated with rituximab have a 90% 5-year survival rate

62% - 1 in 3 die

MCD is as deadly as cancer

Patients are commonly misdiagnosed with other illnesses or told they have cancer before being correctly diagnosed with Castleman disease. Many patients are relieved to find out they do not have cancer, but Multicentric Castleman disease has a nearly identical 5-year mortality rate as colon cancer (35%) and a worse mortality rate than prostate cancer, breast cancer, non-Hodgkin lymphoma, and Hodgkin lymphoma. Multicentric Castleman disease is also often treated with chemotherapy that is also used for cancer.

Not that rare: As common as ALS

Recent estimates suggest the incidence of all subtypes of Castleman disease (UCD, HHV-8-associated MCD, and iMCD) to be approximately 6,500 to 7,700 new cases per year in the US. Multicentric Castleman disease is estimated to account for one in four Castleman disease cases. The disease can occur in males and females at any age, including young children, but UCD is more common in 20-30 year olds; MCD is most common in 40-60 year olds.

While it does not garner the same public awareness as Lou Gehrig's Disease (ALS), just as many Americans are facing this grim disease. ALS has an incidence of 5,600 per year in the US (

ALS and CD

Cancer Risk

Hematologic malignancies are diagnosed at an increased frequency within 2 years of iMCD diagnosis. These malignant cells may have been present all along and actually secreted the IL-6 that was responsible for the preceding iMCD symptoms and diagnosis.  Alternative explanations for the frequent association between iMCD and malignancy include the possibility that iMCD is a "pre-lymphoma" that eventually transforms; excessive cytokine release promotes malignant transformation; iMCD treatments cause or increase susceptibility to secondary malignancies; or an unidentified virus may be responsible for both the iMCD and the malignancy. We suggest that a search for an underlying malignancy be conducted in all newly diagnosed iMCD patients. Further research is needed to better understand the relationship between iMCD and malignancies.

Signs & Symptoms

S and S CD

The clinical spectrum of disease severity is very broad. It ranges from gradual enlargement of lymph nodes with mild symptoms (unicentric CD) to the sudden, intense onset of several of the following systemic symptoms that can be seen with multicentric CD:

  • Fever: 26-52% of iMCD patients were reported to have this symptom1 
  • Night sweats:10-62% of iMCD patients were reported to have this symptom1 
  • Loss of appetite, nausea, and vomiting
  • Unintended weight loss: 16-72% of iMCD patients were reported to have this symptom1
  • Weakness and fatigue
  • Enlarged liver or spleen: 41-78% of iMCD patients were reported to have this symptom1
  • Peripheral neuropathy (numbness in the hands and feet)
  • Eruption of cherry hemangiomas (benign proliferations of blood vessels) on the skin
  • Edema (swelling), ascites (fluid accumulation in the abdomen), and/or other symptoms of fluid overload: 23-78% of iMCD patients were reported to have this symptom1 
  • Decreased urine output and systemic toxicity due to kidney failure
  • Bruising, easy bleeding, and risk of infection due to bone marrow failure

Individuals with MCD will often demonstrate several of the following abnormal laboratory values:

  • Elevated erythrocyte sedimentation rate (ESR): 34-92% of iMCD patients were reported to have this laboratory abnormality1
  • Elevated C-reactive protein (CRP): 51-82% of iMCD patients were reported to have this laboratory abnormality1
  • Elevated fibrinogen
  • Low hemoglobin (anemia): 62-87% of iMCD patients were reported to have this laboratory abnormality1
  • Low platelet count (thrombocytopenia): 22-44% of iMCD patients were reported to have this laboratory abnormality1
  • Elevated creatinine and BUN, proteinuria: 9-71% of iMCD patients were reported to have high creatinine or high BUN1
  • Low albumin: 45-90% of iMCD patients were reported to have this laboratory abnormality1
  • Polyclonal lymphocytes 
  • Elevated IL-6: 45-90% of iMCD patients were reported to have this laboratory abnormality1
  • Elevated VEGF: 13-80% of iMCD patients were reported to have this laboratory abnormality1
  • Autoimmune antibodies, such as positive anti-nuclear antibody, anti-erythrocyte autoantibodies, and anti-platelet antibodies: 9-71% of iMCD patients were reported to have a positive Coombs testand 12-37% of iMCD patients were reported to have positive ANA test1
  • Hypergammaglobulinemia: 49-77% of iMCD patients were reported to have this laboratory abnormality1

Reference: 1 Liu, A. Y., Nabel, C. S., Finkelman, B. S., Ruth, J. R., Kurzrock, R., van Rhee, F., ... & Fajgenbaum, D. C. (2016). Idiopathic multicentric Castleman's disease: a systematic literature review. The Lancet Haematology3(4), e163-e175.

CD lymph nodes demonstrate several characteristics, which can be divided into one of four variants: hyaline-vascular (HV), plasma cell (PC), mixed, and plasmablastic.

HV is characterized by widened mantle zones composed of concentric rings of small lymphocytes in an “onion skin” pattern around small atrophic germinal centers with penetrating hyalinized vessels and dysplastic follicular dendritic cells (FDCs). In PC, the germinal centers are hyperplastic rather than atrophic, the interfollicular region contains sheets of plasma cells and vascular proliferations, the FDC network is normal, and there is preserved lymph node architecture. The mixed variant displays features of both HV and PC. The plasmablastic variant is only found in HHV-8-associated MCD.

The reliability and significance of these variants is unclear, as there are reports of transitions between HV and PC variants on subsequent biopsies, as well as the simultaneous presence of both types at separate sites within the same patient.

Raj Jayanthan, CDCN Director of Patient Engagement, describes his experience as a patient:



The first-ever diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease has been developed by the CDCN and published in Blood. After reviewing 244 cases, meeting twice, and refining diagnostic criteria over a 15 month period, a panel of international experts came up with the below diagnostic criteria for idiopathic multicentric Castleman disease. Please click here to use our HHV-8-negative/"idiopathic" multicentric Castleman disease Diagnostic Calculator. The Diagnostic Calculator can be used to determine if the disease features present in a patient are consistent with a diagnosis of idiopathic multicentric Castleman disease using the international, evidence-based consensus diagnostic criteria. However, please note that the Diagnostic Calculator is provided as an informational resource only and is not to be used or relied on for any diagnostic or treatment purposes.

Major Diagnostic Criteria (need both present to diagnose)

  1. Histopathological lymph node features consistent with the idiopathic multicentric Castleman disease spectrum Features along the idiopathic multicentric Castleman disease spectrum include (need Grade 2-3 for either regressive germinal centers or plasmacytosis at minimum): 
Regressive/atrophic/atretic germinal centers, often with expanded mantle zones composed of concentric rings of lymphocytes in an ‘onion skinning’ appearance Follicular dendritic cell prominence
Vascularity, often with prominent endothelium in the interfollicluar space and vessels penetrating into the germinal centers with a ‘lollipop appearance’ Sheet-like, polytypic plasmacytosis in the interfollicular space 
Hyperplastic germinal centers 

  2. Enlarged lymph nodes (>1cm in short-axis diameter) in two or more lymph node stations 

Minor Criteria (need at least 2 out of 11 criteria with at least 1 laboratory criterion) 


  1. Elevated CRP (greater than 10mg/L) or ESR (greater than 15mm/hr)

  2. Anemia (hemoglobin less than 12.5g/dL for males, hemoglobin less than 11.5g/dL for 

  3. Thrombocytopenia (platelet count less than 150k/μL) or thrombocytosis (platelet count 
greater than 400k/μL) 

  4. Hypoalbuminemia (albumin less than 3.5g/dL) 

  5. Renal dysfunction (eGFR <60 mL/min/1.73m2) or proteinuria (total protein >150mg/100ml) 

  6. Polyclonal hypergammaglobulinemia (total gamma globulin or immunoglobulin 
G >1700mg/dL) 


  1. Constitutional symptoms: night sweats, fever (>38oC), weight loss, or fatigue (>2 CTCAE lymphoma score for B-symptoms) 

  2. Large spleen and/or liver 

  3. Fluid accumulation: edema, anasarca, ascites, or pleural effusion 

  4. Eruptive cherry hemangiomatosis or violaceous papules 

  5. Lymphocytic interstitial pneumonitis 

Exclusion Criteria

In addition to the above criteria, the diagnosis requires that the following be excluded to rule out other conditions that mimic idiopathic multicentric Castleman disease.

Infection Related Disorders:

  1. HHV-8 (infection can be documented by blood PCR, diagnosis of HHV-8-associated MCD requires positive LANA-1 staining by IHC, which excludes idiopathic multicentric Castleman disease) 

  2. Clinical EBV-lymphoproliferative disorders such as infectious mononucleosis or chronic active EBV (Detectable EBV viral load not necessarily exclusionary) 

  3. Inflammation and adenopathy due to other uncontrolled infections, e.g. acute or uncontrolled CMV, toxoplasmosis, HIV, active tuberculosis 

Autoimmune/autoinflammatory diseases (requires full clinical criteria, detection of autoimmune antibodies alone is not exclusionary):

  1. Systemic lupus erythematosus 

  2. Rheumatoid arthritis 

  3. Adult-onset Still disease 

  4. Juvenile idiopathic arthritis 

  5. Autoimmune lymphoproliferative syndrome (ALPS) 

Malignant/lymphoproliferative disorders (these disorders must be diagnosed before or at the same time as iMCD to be exclusionary):

  1. Lymphoma (Hodgkin and non-Hodgkin) 

  2. Multiple myeloma 

  3. Primary lymph node plasmacytoma 

  4. Follicular dendritic cell sarcoma 

  5. POEMS syndrome


Readers are strongly encouraged to read the paper in its entirely at BloodFajgenbaum DC, Uldrick TS, Bagg A, et al.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. Published online January 13, 2017; doi:10.1182/blood-2016-10-746933 

No official criteria exists for diagnosing UCD or HHV-8-associated MCD.

Diagnosis is further complicated by the fact that several disorders are reported to occur simultaneously with CD, which may or may not be responsible for the CD. A list of these is provided below.

Neoplastic Inflammatory Infectious
POEMS Syndrome

Adult Onset Still’s Disease

Human Herpes Virus 6
Paraneoplastic Pemphigus Systemic Juvenile Idiopathic Arthritis Hepatitis B Virus
Melanoma Sarcoidosis Toxoplasma
Angioimmunoblastic T-cell Lymphoma Amyloidosis Mycobacterium Tuberculosis
Indolent T-Lymphoblastic Proliferation Pure Red Cell Aplasia Cytomegalovirus
Inflammatory Hepatocellular Adenoma Acquired Factor VIII Deficiency Toxoplasma
  Myasthenia Gravis


  Familial Mediterranean Fever  

Dr. Ahmet Dogan presents Castleman Disease Pathology & Diagnosis at a recent ASH meeting:



All cases of UCD and about ½ of MCD are idiopathic—the cause is not known. There are no known risk factors for UCD or idiopathic MCD, though the possibility of a genetic predisposition is under investigation. For approximately ½ of MCD patients, HHV-8 infection causes and drives their disease. In these cases, HIV infection or another immune deficiency (i.e. genetic, immunosuppressants) enables HHV-8 to escape control by the immune system, replicate in lymph nodes, and signal the release of an excess of inflammatory chemicals (or cytokines), such as Interleukin-6 (IL-6).

In all healthy individuals, cytokines, such as IL-6, are used by the immune system to fight infections and maintain immune system health. However, when too many cytokines, such as IL-6, are released (hypercytokinemia), these cytokines are damaging to organs and inflammatory cells are signaled to replicate quickly.

Idiopathic MCD (iMCD) patients also exhibit high cytokine levels, such as IL-6, but the cause of the cytokine release is not known. Fajgenbaum, van Rhee, and Nabel recently proposed that iMCD represents a common end point that can be reached through multiple processes, each involving immune dysregulation and a common pathway of elevated proinflammatory cytokine release. They hypothesize that one or more of the following three candidate processes are responsible for driving iMCD hypercytokinemia: (1) autoimmune/autoinflammatory mechanisms via autoantibody antigenic stimulation or a germ-line genetic aberration in innate immune regulation (systemic inflammatory disease hypothesis), (2) ectopic cytokine secretion by malignant or benign tumor cells within the lymph nodes or extranodal (paraneoplastic syndrome hypothesis), and (3) viral signaling by a non-HHV-8 virus (virally driven hypothesis).


Please visit our Therapeutic Target Database for information about treatment options for iMCD, UCD, HHV-8-associated MCD and POEMS-associated MCD. You can also watch Dr. Frits van Rhee, CDCN co-founder, describe updates on Castleman disease treatment at a recent ASH meeting:

Dr. Sunita Nasta shares her thoughts on the current status of Castleman disease research and resources for patients:


Prognosis and Survival

The average length of survival after UCD diagnosis is greater than 10 years, and life expectancy is usually not changed by UCD. 

MCD: The 5-year overall survival rate was 65% in a 2012 series of MCD cases (40% at 10 years; up from 13% in a 1993 series of 38 patients). Further progress in long-term outcome is anticipated with the advent of antibodies targeting the IL-6 signaling cascade, such as tocilizumab and siltuximab. The CDCN is currently spearheading a global patient registry to collect data on effective treatments and their relation to long term survival.

mortality CD

New Framework

Before the CDCN, the medical community believed that 'benign lymph node tumors’ secreted Interleukin-6 (IL-6), which caused the activated immune system and organ dysfunction seen in MCD. When we combined experiences by the CDCN community from hundreds of unpublished iMCD cases with the published literature for iMCD and HHV-8-associated MCD, a potential new model disease framework emerged. Our new framework suggests that the enlarged lymph nodes are not IL-6-secreting “tumors” but are actually caused by the excess IL-6 and other proinflammatory proteins produced by an activated immune system. In essence, what we used to think was the cause (enlarged lymph node) is actually an effect and now we're trying to figure out the cause. Importantly, we now think about MCD as a hyperinflammatory disorder instead of a benign lymphoproliferative disorder.

Dr. David Fajgenbaum, co-founder & Executive Director of the CDCN, addressed the Wharton Health Care Business Conference on a new framework for Castleman disease:

We are blazing a path to a cure

There are many unanswered questions about Castleman disease, which make treatment difficult. In fact, researchers and physicians do NOT yet know:

  • Which cell is the problem cell (or “Castleman cell”)?

  • What cellular signaling pathways are activated?

  • What are all of the chemicals being secreted by these activated cells?

With experts from around the globe working together and a community of patients fighting back, we can answer these questions and stomp out this disease.